# US 2026/0218158 A1 · Mutant aminoacyl trna synthetase, compositions comprising same, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218158 A1
- Document ID: US20260218158A1
- Status: Published application
- Kind: A1
- Application number: 19/140,276
- Filed: 2024-01-02
- Published: 2026-07-30
- Earliest claimed: 2023-01-02
- Assignees: B. G. Negev Technologies and Applications Ltd., At Ben-Gurion University
- Applicants: B. G. Negev Technologies and Applications Ltd., At Ben-Gurion University
- Inventors: Miriam AMIRAM; Daniela STRUGACH
- Web page: https://patentgrep.com/patent/US20260218158A1

## CPC

- C12N 9/93: {Ligases (6)}
- C12N 15/67: General methods for enhancing the expression
- C12N 13/00: Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12Y 601/01: Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES

## Abstract

The present invention provides a protein including the amino acid sequence of SEQ ID NO: 7, wherein isoleucine at position 159 is substituted with Ser or Asp. Further provided are composition comprising the protein disclosed herein, as well as methods of using same, such as for producing a protein of interest including a non-standard amino acid.

## Claims

### Claim 1

A protein comprising the amino acid sequence of SEQ ID NO: 7, wherein isoleucine at position 159 (I159) is substituted with Ser or Asp.

### Claim 2 (depends on 1)

The protein of claim 1, further comprising a substitution in at least one position selected from the group consisting of: 158, 162, 167, and any combination thereof, of SEQ ID NO: 7, wherein any one of: aspartate at position 158 (D158) is substituted with Cys, Met, Gly, Tyr, or Ile, leucin at position 162 (L162) is substituted with Gly, Tyr, or Asp, alanine at position 167 (A167) is substituted with Leu, Thr, or Tyr, and any combination thereof.

### Claim 3 (depends on 1)

The protein of claim 1, comprising said I159 being substituted with Asp (I159D), and optionally wherein said protein comprises any one of: said D158 being substituted with Cys (D158C), said L162 being substituted with Gly (L162G), said A167 being substituted with Leu (A167L), and any combination thereof, and optionally wherein said protein comprises said D158C, said I159D, said L162G, and said A167L.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The protein of claim 1, further comprising a substitution in at least one position selected from the group consisting of: 32, 65, 257, 286, of SEQ ID NO: 7, wherein any one of: tyrosine at position 32 (Y32) being substituted with Gly, leucin at position (L65) being substituted with Val, arginine at position (R257) being substituted with Gly, aspartate at position 286 (D286) being substituted with Arg, and any combination thereof.

### Claim 7 (depends on 1)

The protein of claim 1, comprising an amino acid sequence having not more than 98% sequence homology or identity to SEQ ID NO: 7.

### Claim 8 (depends on 1)

The protein of claim 1, comprising an amino acid sequence set forth in any one of: SEQ ID Nos: 1-5, or a functional analog thereof having at least 95% homology thereto.

### Claim 9 (depends on 1)

The protein of claim 1, comprising an amino acid sequence set forth in SEQ ID NO: 4.

### Claim 10 (depends on 1)

The protein of claim 1, characterized by being capable of pairing a non-standard amino acid (nsAA) with a tRNA, optionally wherein said nsAA comprises a photo-switchable group, and optionally wherein said photo-switchable group is characterized by the structure:
wherein R independently represents an optional substituted alkyl or H;
wherein R1 represents one or more substituents, wherein each of said one or more substituents is independently selected from the group consisting of C1-C6 alkyl, halo, NO2, CN, OH, NH2, carbonyl, CONH2, CONR′2, CNNR2, CSNR2, CONH—OH, CONH—NH2, NHCOR′, NHCSR′, NHCNR′, —NC(O)OR′, —NC(═O)NR′, —NC(═S)OR′, —NC(═S)NR′, SO2R′, SOR′, —SR′, SO2OR′, SO2N(R′)2, —NHNR′2, —NNR′, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy(C1-C6 alkyl), hydroxy(C1-C6 alkoxy), alkoxy(C1-C6 alkyl), alkoxy(C1-C6 alkoxy), amino(C1-C6 alkyl), CONH(C1-C6 alkyl), CON(C1-C6 alkyl)2, CO2H, CO2R′, —OCOR′, —OCOR′, —OC(═O)OR′, —OC(O)NR′, —OC(═S)OR′, —OC(═S)NR′, a heteroatom, a cyclyl, an optionally substituted cycloalkyl, optionally substituted heterocyclyl, and a combination thereof, wherein each R′ is independently selected from hydrogen, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, optionally bonded through a ring carbon, or through a heteroatom) or heterocyclyl, optionally bonded through a ring carbon, or through a heteroatom); wherein X is a bond or an alkyl; and wherein a wavy bond represents an attachment point to a backbone of the nsAA.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 10)

The protein of claim 10, wherein any one of: (i) said nsAA comprises arylazopyrazole (AAP); (ii) said tRNA comprises an anticodon complementary to a stop codon; and (iii) both (i) and (ii), and optionally wherein said stop codon is an amber codon (UAG).

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 1)

An artificial or synthetic nucleic acid molecule comprising a polynucleotide encoding the protein of claim 1, and optionally wherein said artificial or synthetic nucleic acid molecule being an expression vector or a plasmid.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

A cell comprising the protein of claim 1, and optionally wherein said cell being a bacterial cell.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

A composition comprising the protein of claim 1, and an acceptable carrier.

### Claim 22 (depends on 21)

The composition of claim 21, further comprising: (i) a tRNA comprising an anticodon complementary to a stop codon, a nsAA, or both; (ii) a tRNA comprising an anticodon complementary to a stop codon paired to a nsAA; or both (i) and (ii).

### Claim 23

(canceled)

### Claim 24 (depends on 22)

The composition of claim 22, wherein said stop codon is an amber codon (UAG).

### Claim 25 (depends on 1)

A method for producing a protein of interest (POI) comprising a nsAA, the method comprising culturing a cell comprising a polynucleotide encoding said POI and comprising a premature stop codon, under conditions sufficient for expression of said polynucleotide, wherein said cell comprises the protein of claim 1, thereby producing the POI comprising a nsAA.

### Claim 26 (depends on 25)

The method of claim 25, wherein said culturing comprises supplementing said cell with an effective amount of said nsAA.

### Claim 27 (depends on 25)

The method of claim 25, wherein said producing comprises increasing production levels of said POI comprising said nsAA, compared to a control, and optionally wherein said increasing is by at least 1.5-fold compared to said control.

### Claim 28

(canceled)

### Claim 29 (depends on 25)

The method of claim 25, wherein said nsAA comprises a photo-switchable group.

### Claim 30 (depends on 25)

The method of claim 25, wherein said photo-switchable group is characterized by the structure:
wherein R independently represents an optional substituted alkyl or H;
wherein R1 represents one or more substituents, wherein each of said one or more substituents is independently selected from the group consisting of C1-C6 alkyl, halo, NO2, CN, OH, NH2, carbonyl, CONH2, CONR′2, CNNR2, CSNR2, CONH—OH, CONH—NH2, NHCOR′,NHCSR′, NHCNR′, —NC(═O)OR′, —NC(═O)NR′, —NC(═S)OR′, —NC(═S)NR′, SO2R′, SOR′, —SR′, SO2OR′, SO2N(R′)2, —NHNR′2, —NNR′, NH(C1-C6 alkyl), N(C1-C6 alkyl)2, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxy(C1-C6 alkyl), hydroxy(C1-C6 alkoxy), alkoxy(C1-C6 alkyl), alkoxy(C1-C6 alkoxy), amino(C1-C6 alkyl), CONH(C1-C6 alkyl), CON(C1-C6 alkyl)2, CO2H, CO2R′, —OCOR′, —OCOR′, —OC(═O)OR′, —OC(═O)NR′, —OC(═S)OR′, —OC(═S)NR′, a heteroatom, a cyclyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, and a combination thereof, wherein each R′ is independently selected from hydrogen, alkyl, cycloalkyl, alkenyl, aryl, heteroaryl, optionally bonded through a ring carbon, or through a heteroatom) or heterocyclyl, optionally bonded through a ring carbon, or through a heteroatom); wherein X is a bond or an alkyl; and wherein a wavy bond represents an attachment point to a backbone of the nsAA.

### Claim 31 (depends on 25)

The method of claim 25, further comprising a step comprising subjecting said produced POI comprising said nsAA to light at a wavelength configured to induce conformational switch of said photo-switchable group.
